64 citations
Counting papers with at most 25 authors, so collaboration author lists do not stand in for the people here.
- Novartis (Switzerland)CH6 papers
- Medical University of ViennaAT3 papers
- Statistics AustriaAT3 papers
- Novartis (China)CN2 papers
- University Hospital MagdeburgDE2 papers
- AstraZeneca (Sweden)SE1 paper
- Berry & Associates (United States)US1 paper
- Berry Consultants, LLC (United States)US1 paper
- Charité - Universitätsmedizin BerlinDE1 paper
- Constellium (United Kingdom)GB1 paper
- Franklin UniversityUS1 paper
- Institute of Neuroimmunology and Multiple SclerosisDE1 paper
3 papers · 1 filter
Using Individualized Treatment Effects to Assess Treatment Effect Heterogeneity
Konstantinos Sechidis, Cong Zhang, Sophie Sun +3
Assessing treatment effect heterogeneity (TEH) in clinical trials is crucial, as it provides insights into the variability of treatment responses among patients, influencing import…
WATCH: A Workflow to Assess Treatment Effect Heterogeneity in Drug Development for Clinical Trial Sponsors
Konstantinos Sechidis, Sophie Sun, Yao Chen +8
This paper proposes a Workflow for Assessing Treatment effeCt Heterogeneity (WATCH) in clinical drug development targeted at clinical trial sponsors. WATCH is designed to address t…
Decision rules for identifying combination therapies in open-entry, randomized controlled platform trials
Elias Laurin Meyer, Peter Mesenbrink, Cornelia Dunger-Baldauf +3
Platform trials have become increasingly popular for drug development programs, attracting interest from statisticians, clinicians and regulatory agencies. Many statistical questio…